The Madras High Court's ruling in Novartis AG v. Venkata Narayana Active Ingredients delineates the evidentiary standards necessary to invoke the Bolar exemption for regulatory approval purposes. This clarification aims to mitigate burdens on manufacturers.
Madras High Court Clarifies Burdens of Bolar Exemption
On August 14, 2026, the Madras High Court rendered a critical judgment in Novartis AG v. Venkata Narayana Active Ingredients, addressing the evidentiary requirements for invoking the Bolar exemption under Section 107A of the Patents Act. The ruling marks a progressive step towards clarifying the evidentiary burdens on manufacturers seeking regulatory approvals for generic drugs.
The Court emphasized that while the Bolar exemption allows for certain activities to hasten drug approval processes, the evidentiary standards must still be sufficiently rigorous to ensure that rights holders are not undermined. This balance is crucial in maintaining the intended purpose of the Bolar exemption while not stifling innovation.
Practitioners in the pharmaceutical sector should take note of this ruling, as it establishes a clearer framework within which companies must operate to navigate the complexities of patent law and regulatory compliance.
